Clinical Evaluation of the Levitation Knee Brace
Launched by UNIVERSITY OF CALGARY · Sep 15, 2022
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
Osteoarthritis (OA) is a debilitating musculoskeletal disease affecting approximately 1/3 of Canadians over age 25. The disease is characterized by loss of cartilage in the afflicted joint and can be a major source of pain, disability, and reduced quality of life. The direct cost of OA in Canada was $2.9 billion CAD in 2010 and is expected to rise to $7.6 billion CAD by 2031. Total knee replacement (TKR) is often used to restore mobility, and the risk for expensive and invasive revision surgery is 2-5 times higher in OA patients younger than 65 years. Thus, finding an alternate early treatm...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patellofemoral of combined patellofemoral and tibiofemoral knee osteoarthritis
- • Kellgren-Lawrence grade ≥ 2 osteoarthritis (moderate-severe) on weight bearing tunnel view x-ray + skyline
- • Experience knee pain that worsens (VAS pain score ≥ 4) with activities such as squatting, rising from seated, and going up and down stairs
- • Experience less pain (VAS pain score) in the contralateral knee than in the affected knee during weight-bearing activities
- • \< 7 degrees of varus/valgus knee alignment
- • Knee flexion/extension range of motion from 5-100 degrees minimum
- • Between the ages of 18-80
- • Able to hear and understand study information and instructions in English
- • Must be able to be fit with a Levitation knee brace
- Exclusion Criteria:
- • History of arthroplasty or high tibial osteotomy in the affected limb
- • Surgery (excluding arthroscopy) on either lower limb within last 6 months
- • Arthroscopic debridement of the affected knee within last 3 months
- • Received corticosteroid injections in last 3 months
- • Received hyaluronic acid or platelet-rich plasma (PRP) injections in last 6 months
- • History of rheumatoid arthritis
- • Symptomatic disease of the hip, ankle, or foot
- • History of traumatic onset of knee pain
- • A major lower limb injury within the past year requiring physiotherapy or surgery
- • Previous fracture of the tibia or femur of the affected limb
- • History of diabetic neuropathy or peripheral vascular disease
- • Parkinson's or neurodegenerative order that may affect balance / ability to ambulate
- • Use of a non-study provided knee brace on the affected limb over the study period
- • Known allergy or adverse skin reaction to neoprene
- • Open skin wounds present on the leg of the affected side
- • Unable to physically or mentally comply with the wearing of a knee brace
- • Any contraindications for knee bracing
About University Of Calgary
The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Patients applied
Trial Officials
Janet L Ronsky, PhD
Principal Investigator
University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials